476 related articles for article (PubMed ID: 15059651)
1. Turning tumor cells in situ into T-helper cell-stimulating, MHC class II tumor epitope-presenters: immuno-curing and immuno-consolidation.
Hillman GG; Kallinteris NL; Lu X; Wang Y; Wright JL; Li Y; Wu S; Forman JD; Gulfo JV; Humphreys RE; Xu M
Cancer Treat Rev; 2004 May; 30(3):281-90. PubMed ID: 15059651
[TBL] [Abstract][Full Text] [Related]
2. Forcing tumor cells to present their own tumor antigens to the immune system: a necessary design for an efficient tumor immunotherapy.
Humphreys RE; Hillman GG; von Hofe E; Xu M
Cell Mol Immunol; 2004 Jun; 1(3):180-5. PubMed ID: 16219165
[TBL] [Abstract][Full Text] [Related]
3. Genetic approaches for the induction of a CD4+ T cell response in cancer immunotherapy.
Bonehill A; Heirman C; Thielemans K
J Gene Med; 2005 Jun; 7(6):686-95. PubMed ID: 15693037
[TBL] [Abstract][Full Text] [Related]
4. Immune selection in murine tumors. Ph.d thesis.
Svane IM; Engel AM
APMIS Suppl; 2003; (106):1-46. PubMed ID: 12739251
[TBL] [Abstract][Full Text] [Related]
5. Tumor cells engineered to express major histocompatibility complex class II molecules induce T helper cell-dependent responses that protect mice from normally lethal doses of unmodified tumor cells.
Callahan GN; Leach DR
Cancer Detect Prev; 1996; 20(3):199-206. PubMed ID: 8769713
[TBL] [Abstract][Full Text] [Related]
6. Superior tumor protection induced by a cellular vaccine carrying a tumor-specific T helper epitope by genetic exchange of the class II-associated invariant chain peptide.
van Bergen J; Camps M; Offringa R; Melief CJ; Ossendorp F; Koning F
Cancer Res; 2000 Nov; 60(22):6427-33. PubMed ID: 11103809
[TBL] [Abstract][Full Text] [Related]
7. Direct identification of human tumor-associated peptide antigens and a preclinical model to evaluate their use.
Engelhard VH; Bullock TN; Colella TA; Mullins DW
Cancer J; 2000 May; 6 Suppl 3():S272-80. PubMed ID: 10874498
[TBL] [Abstract][Full Text] [Related]
8. A novel strategy for the discovery of MHC class II-restricted tumor antigens: identification of a melanotransferrin helper T-cell epitope.
Röhn TA; Reitz A; Paschen A; Nguyen XD; Schadendorf D; Vogt AB; Kropshofer H
Cancer Res; 2005 Nov; 65(21):10068-78. PubMed ID: 16267033
[TBL] [Abstract][Full Text] [Related]
9. MHC class II-restricted tumor antigens recognized by CD4+ T cells: new strategies for cancer vaccine design.
Zeng G
J Immunother; 2001; 24(3):195-204. PubMed ID: 11394496
[TBL] [Abstract][Full Text] [Related]
10. Generating MHC Class II+/Ii- phenotype after adenoviral delivery of both an expressible gene for MHC Class II inducer and an antisense Ii-RNA construct in tumor cells.
Hillman GG; Kallinteris NL; Li J; Wang Y; Lu X; Li Y; Wu S; Wright JL; Slos P; Gulfo JV; Humphreys RE; Xu M
Gene Ther; 2003 Aug; 10(17):1512-8. PubMed ID: 12900767
[TBL] [Abstract][Full Text] [Related]
11. Augmenting major histocompatibility complex class I expression by murine tumors in vivo enhances antitumor immunity induced by an active immunotherapy strategy.
Merritt RE; Yamada RE; Crystal RG; Korst RJ
J Thorac Cardiovasc Surg; 2004 Feb; 127(2):355-64. PubMed ID: 14762342
[TBL] [Abstract][Full Text] [Related]
12. Major histocompatibility complex-restricted and unrestricted activation of helper T cell lines by liposome-bound antigens.
Walden P; Nagy ZA; Klein J
J Mol Cell Immunol; 1986; 2(4):191-7. PubMed ID: 2978228
[TBL] [Abstract][Full Text] [Related]
13. Tumor cells transduced with the MHC class II Transactivator and CD80 activate tumor-specific CD4+ T cells whether or not they are silenced for invariant chain.
Thompson JA; Dissanayake SK; Ksander BR; Knutson KL; Disis ML; Ostrand-Rosenberg S
Cancer Res; 2006 Jan; 66(2):1147-54. PubMed ID: 16424052
[TBL] [Abstract][Full Text] [Related]
14. Active CD4+ helper T cells directly stimulate CD8+ cytotoxic T lymphocyte responses in wild-type and MHC II gene knockout C57BL/6 mice and transgenic RIP-mOVA mice expressing islet beta-cell ovalbumin antigen leading to diabetes.
Ye Z; Ahmed KA; Hao S; Zhang X; Xie Y; Munegowda MA; Meng Q; Chibbar R; Xiang J
Autoimmunity; 2008 Nov; 41(7):501-11. PubMed ID: 18855194
[TBL] [Abstract][Full Text] [Related]
15. CD4+ T helper cell response is required for memory in CD8+ T lymphocytes induced by a poly(I:C)-adjuvanted MHC I-restricted peptide epitope.
Qiu F; Cui Z
J Immunother; 2007; 30(2):180-9. PubMed ID: 17471165
[TBL] [Abstract][Full Text] [Related]
16. Ii-Key/HPV16 E7 hybrid peptide immunotherapy for HPV16+ cancers.
Xu M; Lu X; Sposato M; Zinckgraf JW; Wu S; von Hofe E
Vaccine; 2009 Jul; 27(34):4641-7. PubMed ID: 19520206
[TBL] [Abstract][Full Text] [Related]
17. Immune responses to a class II helper peptide epitope in patients with stage III/IV resected melanoma.
Wong R; Lau R; Chang J; Kuus-Reichel T; Brichard V; Bruck C; Weber J
Clin Cancer Res; 2004 Aug; 10(15):5004-13. PubMed ID: 15297401
[TBL] [Abstract][Full Text] [Related]
18. Evidence implicating L3T4 in class II MHC antigen reactivity; monoclonal antibody GK1.5 (anti-L3T4a) blocks class II MHC antigen-specific proliferation, release of lymphokines, and binding by cloned murine helper T lymphocyte lines.
Wilde DB; Marrack P; Kappler J; Dialynas DP; Fitch FW
J Immunol; 1983 Nov; 131(5):2178-83. PubMed ID: 6195255
[TBL] [Abstract][Full Text] [Related]
19. Induction of EBV-latent membrane protein 1-specific MHC class II-restricted T-cell responses against natural killer lymphoma cells.
Kobayashi H; Nagato T; Takahara M; Sato K; Kimura S; Aoki N; Azumi M; Tateno M; Harabuchi Y; Celis E
Cancer Res; 2008 Feb; 68(3):901-8. PubMed ID: 18245493
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy of cancer by antisense inhibition of Ii protein, an immunoregulator of antigen selection by MHC class II molecules.
Xu M; Lu X; Kallinteris NL; Wang Y; Wu S; von Hofe E; Gulfo JV; Humphreys RE; Hillman GG
Curr Opin Mol Ther; 2004 Apr; 6(2):160-5. PubMed ID: 15195928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
